Introduction demonstrated the potential of cationic liposomes in gene Gene therapy could represent an important advance in therapy, they have also revealed the insufficient activity the treatment of both inherited and acquired diseases. 1, 2 of gene transfer of the first generation cationic lipoSuccess of human gene therapy depends upon the develsomes. 14 Thus, substantial effort has been spent towards opment of delivery vehicles or vectors which can selecimproving their efficiency. These are largely based on our tively deliver therapeutic genes to target cells with better understanding of the structure/function relationefficiency and safety. Viral vectors, although highly ship of the cationic lipids. [15] [16] [17] For example, transfection efficient, suffer from a number of problems such as efficiency can be improved significantly by designing and immunogenicity, 3 toxicity 4 and potential recombination synthesizing new lipids. 17, 18 Cationic lipid-DNA comor complementation. 5 As a result of these limitations, plexes can also be prepared in such a way that they are much effort has been devoted to the development of nonhighly efficient and serum resistant. [19] [20] [21] [22] Another direcviral vectors, such as cationic liposomes 6, 7 and cationic tion of research aimed at improving the efficiency of lipopolymers. 8, 9 Cationic liposomes are particularly attractive fection is based on the effort to condense DNA in a mandue to their favorable characteristics such as biodegradner similar to natural vectors such as virus and sperm. ability, minimal toxicity, nonimmunogenicity, relative These studies are aimed at developing a nonviral, selfease of large-scale production and simplicity of use. Since assembling system, or 'artificial virus'. 23 Recent study in the description of the first cationic lipid by Felgner in our laboratory has led to the development of a novel 1987, 10 numerous new lipids have been reported. 6,7 Curformulation, ie liposome-polycation-DNA complexes rently, cationic liposomes are widely employed for the (LPD) . 24 It involves the use of a cationic polymer in transfection of eukaryotic cells in research laboratories.
addition to a cationic lipid to condense DNA. Interaction Several liposomal formulations have also undergone of these components at an appropriate ratio results in the clinical evaluation as vectors for gene therapy in cancer formation of a condensed DNA core coated with a lipidic and cystic fibrosis. appropriately formulated, gives high gene expression in methyl-ethane)-carbamoyl]-cholesterol (TC-chol) and dimethyl-dioctadecyl-ammonium bromide (DDAB). vivo, particularly in the lung, following intravenous administration.
However, the efficiency of gene expression differed greatly among these lipids whether as lipid-DNA complexes or as LPD with the highest gene expression found
Results
with DOTAP. The in vivo gene expression of LPD was also increased In vivo gene expression of LPD is charge ratio (+/−) with increasing amounts of protamine. However, LPD dependent became unstable and tended to form large aggregates The charge ratio of either LPD or DOTAP-DNA comwhen the charge ratio of protamine-DNA was greater plexes is calculated based on the assumptions that 1 nmol than 2:1. Therefore, a 1:1 charge ratio of protamine-DNA of DOTAP and protamine sulfate contribute 1 and 21
was employed for LPD in all subsequent studies. nmols of positive charge, respectively, and that 1 g DNA has 3.1 nmols of negative charge. LPD was preDose effect and duration of gene expression pared by mixing protamine with DNA at a +/− charge Figure 2 depicts the gene expression of LPD as a function ratio of 1:1 followed by the addition of varying concenof DNA concentration. The lipid:DNA charge ratio was trations of DOTAP liposomes. The size of the resulting 11:1 for all doses and the injection volume was 300 l. complexes ranged from 200 to 300 nm in diameter. Figure  Increasing the amount of DNA led to a steady increase 1 shows the in vivo gene expression of LPD as a function in gene expression in all the tissues examined, except for of DOTAP concentration. The amount of DNA used was the spleen in which gene expression was saturated when 50 g per mouse. It can be seen that gene expression was the dose reached 50 g per mouse. The lung remained found in all tissues examined, including heart, lung, liver, the tissue with the highest level of gene expression at all spleen and kidney, with the highest expression found in doses tested. Gene expression in the heart was increased the lung. Increasing the amount of DOTAP resulted in a significantly when the DNA dose was increased to 75 g steady increase in gene expression in the lung and spleen;
per mouse. One of the three mice died of toxicity when however, the extent of charge ratio dependence was using 100 g of DNA per mouse, yet no signs of toxicity closely related to the dose of DNA. The charge ratio were noticed when the dose used was 75 g DNA per dependence was more striking when a low dose of DNA mouse or below. was used and became less obvious with increasing Figure 3 shows the duration of gene expression by amounts of DNA (data not shown). The requirement of LPD. The amount of DNA injected was 50 g per mouse high +/− charge ratio for efficient in vivo gene transfer and the lipid:DNA charge ratio was 11:1. Transgene seems to be a general phenomenon for cationic lipids as expression was detected as early as 1 h following i.v. a similar pattern was also found when other cationic lipinjection of LPD, peaked at 6 h and declined thereafter. ids were used, including 3-␤-[N-(N′-N′-dimethyl-ethane)-Gene expression in the lung was significantly higher (n = 3). expression lasted up to 2 days in the lung. Four days after injection of LPD, gene expression could still be detected in the lung, spleen and liver.
Sequential injection of protamine-DNA complexes and free DOTAP liposomes While a high DOTAP:DNA molar ratio is essential for the efficient in vivo gene transfer by LPD, it is conceivable that significant amounts of DOTAP liposomes remain free in the LPD preparations. To better understand how the free cationic liposomes help to improve the in vivo performance of LPD, protamine-DNA complexes and free DOTAP liposomes were i.v. administered separately at intervals of 3 min and 15 min, respectively, and gene lowed by the injection of DOTAP liposomes. In another experiment, DOTAP liposomes were administered first, followed by the injection of protamine-DNA complexes.
The results of both experiments are shown in Figure 4 . of transgene product could be detected in the spleen. Reversing the sequence of the two injections significantly When the duration of the interval between the two injections was 3 min, gene expression in the lung was reduced increased gene expression in the lung. The level of expression, however, varied greatly among different aniby three-to five-fold as compared with co-injection, ie the regular LPD protocol. No significant differences were mals of the same experiment and also differed significantly from experiment to experiment (n = 4) (data not found with respect to the order of which component was injected first. Prolonging the interval between the two shown). No difference in toxicity was found whether animals were treated with LPD or received separate injecinjections from 3 to 15 min further decreased the level of gene expression in vivo, especially when protamine-DNA tions of protamine-DNA complexes and DOTAP liposomes. complexes were administered first. Only minimal activity In and distribution of DNA and lipid in the liver and lung were followed after injection of protamine-DNA complexes, DOTAP liposomes or LPD. The results are shown in Figure 5 . DNA was rapidly removed from circulation by the liver after injection of protamine-DNA complexes, the uptake of DNA by the lung was below 10% of injected dose at all time-points examined. When DNA was formulated in LPD, substantial amounts were trapped in the lung after i.v. injection. Five minutes after injection, about 40% of the injected dose was found in the lung. It was then slowly released from the lung with time and redistributed to the liver.
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In followed a simi- Injection of DOTAP alone showed a tissue distribution similar to that of DOTAP liposomes injected together with protamine-DNA complexes; however, their resiliver. Gene expression was also detected in the spleen upon intraportal injection of LPD. dence in the lung did not last long (data not shown).
Effect of administration routes on the in vivo efficiency
Southern blot analysis of plasmid DNA extracted from the tissues of injected mice of LPD To determine the effect of administration routes on in
The rapid decline of gene expression in vivo might be due to the rapid clearance from the tissues and/or degravivo performance, LPD was also injected intraportally and in vivo gene expression was compared with that of dation within the tissues of the injected DNA. To test this hypothesis, groups of three mice were injected with LPD, intravenous injection. As shown in Figure 6 , gene expression in the lung was reduced dramatically when DOTAP-DNA complexes and protamine-DNA complexes, respectively, and the lung and spleen were col-LPD was injected intraportally. However, gene expression in the lung was still higher than that of the lected at different time-points following the injection. DNA was extracted from the tissues and subjected to Southern blot analysis using luciferase cDNA as a probe. The result is shown in Figure 7 . Plasmid DNA was found in the lungs of mice treated with LPD or DOTAP-DNA complexes 1 and 6 h after i.v. administration but became barely detectable at 24 h. The amount of DNA in LPDtreated mice was higher than those in DOTAP-DNAtreated mice at all time-points examined. No injected plasmid DNA was detected in the lungs in protamine-DNA-treated group at any time-point (Figure 7a ). Analysis of DNA extracted from the spleen exhibited a similar result (Figure 7b ) even though gene expression in the spleen dropped much faster.
In vitro DNaseI protection assay
To confirm further the role of protamine in protecting the DNA from attack by degrading enzymes in vivo, an in vitro DNaseI protection assay was performed. Plasmid DNA was complexed with DOTAP, protamine, or formulated in LPD. By varying the amount of DOTAP, LPD or DOTAP-DNA of different +/− charge ratios were prepared. The result is shown in Figure 8 . At a +/− charge ratio of 4:1, DOTAP offered partial protection for the DNA. In contrast, the DNA was completely protected plexed with DOTAP at the same charge ratio.
Identification of transfected cell type
Having defined the optimal conditions with pCMVL, in vivo gene transfer by LPD was further evaluated using pCMVLacZ as a reporter gene. Mice received intravenous injection of LPD containing lacZ DNA with either a human CMV promoter or promoterless expression system. Twenty-four hours after injection, mice were killed and lungs were fixed and stained for ␤-galactosidase activity using X-gal at 37°C. Figure 9 depicts the appearance of lungs viewed under a dissecting microscope. Homogeneous expression was found in lobes (Figure 9a ) of the mice treated with LPD containing pCMVLacZ. No expression was detected in the lungs of mice treated with promoterless plasmid (Figure 9b ). Similar results were found when the tissue sections of the lobes in Figure 9 were examined under light microscope. No blue cells were observed in the lung treated with promoterless plasmid (Figure 10b ). In contrast there was localized gene expression throughout the distal lung (Figure 10a ) of mouse treated with LPD containing pCMVLacZ. At higher magnification, the primary loci of lacZ expression appeared to be capillary endothelium located within the alveolar septum (Figure 10d ). Endothelial cells were also found to be the cell type transfected in the spleen (data not shown). No sign of inflammation was noticed in all polylysine and protamine of different salt forms vary in their ability to enhance lipofection in vitro. 37 In this study, protamine-free base, protamine phosphate and poly(llysine) hydrobromide were also used to prepare LPD and their in vivo transfection efficiency was compared with that of LPD containing protamine sulfate-USP ( Figure  11) . Consistent with what was found in vitro, protamine sulfate-USP was also the most efficient in enhancing in vivo lipofection. LPD prepared with protamine-free base was not stable and tended to form aggregates. Figure 11 also shows that the protamine sulfate-DNA complexes without lipid were inactive. Protamine-free base-DNA complexes and protamine phosphate-DNA complexes were also not active (data not shown). Naked DNA alone did not give any gene expression in vivo. DOTAP-DNA complexes were effective in transfecting cells in vivo, however, the expression level of the complexes varied from experiment to experiment (the data shown in Figure  11 represent one of the successful experiments). Inclusion of protamine into DOTAP-DNA complexes gave consistently higher gene expression in vivo, particularly in the lung. Normally, inclusion of protamine increased the gene expression of DOTAP-DNA by five-to 10-fold in the lung and 10-to 50-fold in the liver or spleen. Inclusion of protamine was also found to enhance the efficiency of gene delivery by other liposomal formulations including DC-chol, TC-chol and DDAB. 
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DNA as a control. A and I, control plasmid; B, plasmid alone; C, lipo-
Possible mechanisms for this enhancement include some-DNA (+/−, 12/1); D, liposome-DNA (+/−, 4/1); E, liposome-DNA (+/−, 1/1); F, LPD (+/−, 12/1); G, LPD (+/−, 4/1); H, PD (+/−, 1/1).
improved protection of DNA against enzyme attack, 
-Galactosidase staining of lungs 24 h after i.v. injection of LPD containing lacZ cDNA with either a human CMV promoter (a) or promoterless expression system (b). The lung processing and staining were performed as described in Materials and methods, and examined with a dissecting microscope at × 4. Homogeneous expression was apparent in the lobe (a) isolated from mice treated with LPD containing plasmid expression vector with a human CMV promoter; there was no detectable transgene expression in the lung after injection of LPD containing promoterless expression vector (b).
Figure 10 Light photomicrograph of lung sections of the mice injected with LPD containing lacZ cDNA (with a hCMV promoter). Separate lung lobes from mice described in the legend to Figure 9 were embedded in paraffin and thin sections were counterstained and viewed with a Nikon light microscope (Nikon, Garden City, NY, USA) at × 20 (a and b) and × 100 (c and d). There was no detectable lacZ expression in the lung of control mouse (b). In contrast, there was localized expression throughout the distal lung (a, arrows) of mouse injected with LPD containing lacZ with a hCMV promoter. At higher magnification (c and d), expression was seen in structures within the alveolar septum that appeared to be capillary endothelium as evidenced by appearance of X-gal product at both surfaces of the capillary endothelium (double arrows, d).
assistance afforded by the polymer in the nuclear transability to enhance lipofection. A polylysine with a molecular weight of 25 600 was found to be the best among port of plasmid DNA, and more importantly, more efficient uptake by cells of the ternary complexes owing several polymers examined. 24 As part of a continuing effort to improve further the efficiency of LPD, to the favorable structure of the highly condensed, lipidassociated particles. Different polymers or even the same protamine-sulfate was subsequently discovered to be more efficient than polylysine in enhancing lipofection. 37 polymer of different molecular weights vary in their the more consistent in vivo lipofection result when LPD was used. At present, the detailed mechanisms for the improved in vivo lipofection by LPD are not fully understood. One likely mechanism is improved protection of the DNA by LPD as compared with cationic liposomes. This was confirmed in a Southern blot of the DNA extracted from tissues of treated mice ( Figure 7) and DNaseI protection assay (Figure 8) . LPD was more efficient than DOTAP in protecting the DNA from attack by both DNaseI and DNA degrading enzymes in vivo. Interesting to note is that polylysine was more efficient than protamine in protecting the DNA from digestion by DNaseI (data not shown) but less active in enhancing in vivo lipofection. Obviously, other factors may also be important in determining the capacity of a cationic polymer to form an efficient LPD. It should be noted that polylysine was used in this study according to conditions optimized for fore needed before any definite conclusion can be made.
protamine-free base (2), protamine phosphate (3), and protamine sulfate-
It is generally known that lipofection is sensitive to USP (4), respectively, was prepared as described in the legend to Figure 2. serum. 27 A recent study in this laboratory has demon-
PD, protamine sulfate-DNA complexes; LD, DOTAP cationic liposome-DNA complexes. The effect of naked DNA is also shown (n = 3).
strated that serum sensitivity of in vitro lipofection can be overcome by increasing the charge ratio of cationic lipid-DNA. 38 This study also demonstrates that a high It is interesting, however, to find that protamine phos-+/− charge ratio is essential for in vivo gene transfer by phate or protamine-free base worked poorly in enhanc-LPD (Figure 1) . A similar result has been found in a seping lipofection. The reason for the discrepancy among arate study by Liu et al 28 using DOTMA/Tween 80 for protamine of different salt forms remains unknown. Yet, intravenous delivery of DNA. It has been shown recently the data clearly suggest that protamine sulfate is a better by Xu and Szoka 29 that DNA can be released from catcandidate for the preparation of LPD. There are ionic liposome-DNA complexes by various anionic moladditional advantages of utilizing protamine sulfate and ecules in vitro, rendering the DNA more susceptible to these are related to its biocompatibility. Protamine sulfdigestion by DNase I. It was speculated that DNA could ate-USP is nontoxic and only weakly immunogenic in be similarly released from lipid-DNA complexes in vivo, humans and has a record of wide clinical application.
a barrier for cationic lipid-mediated gene transfer. 29 The Recently, LPD containing protamine sulfate-USP has presence of an excess amount of cationic lipid may help been shown to transfect brain tissue efficiently and it is neutralize hostile factors in the serum and therefore procurrently being used in a clinical trial for the treatment tect the integrity of protamine-DNA or LPD. This was of Canavan's disease (During et al, unpublished data) . In supported by our Southern blot analysis of the DNA this study, we further examine the in vivo gene expression extracted from tissues of treated mice: much more DNA by this novel LPD upon i.v. administration.
was detected in the mice treated with LPD as compared As shown in Figure 11 , DOTAP-DNA complexes prowith that in the mice treated with protamine-DNA comduced some gene expression in the lung; however, the plexes ( Figure 7 ). DOTAP liposomes can also prolong the expression level of the complexes varied greatly from residence of intact DNA in tissues particularly in the lung experiment to experiment. This might be due to some as shown in the biodistribution study ( Figure 5 ). Taken subtle difference in the structure of complexes from batch together, these results provide for more efficient interacto batch. It is generally known that cationic lipid-DNA tion of intact DNA with target cells (endothelial cells), complexes are very heterogeneous in structure. 25, 26 Difresulting in a high level of gene expression in vivo. The ferent populations of the complexes may differ greatly in protective role of excess lipids, however, was effectively their sensitivity to serum, uptake by cells and eventually manifested only when they were co-injected with protaintracellular trafficking and gene expression. The way the mine-DNA complexes, ie the regular LPD protocol. Sep-DNA is mixed with liposomes affects the efficiency of the arate administration of protamine-DNA and cationic resulting complexes greatly. 20 It has been shown in a liposomes resulted in a significant reduction in gene recent study that sequential addition of cationic lipid to expression, especially when the interval between the two DNA results in formation of complexes which are not injections was prolonged (Figure 4) . It might be possible only more efficient but also serum resistant. The starting that lipid and protamine-DNA interact with each other concentration of either DNA or liposomes also signifiin the presence of serum to form a new structure which cantly affects the lipofection efficiency. 20 Therefore, prepis efficient in transfecting endothelial cells. Sequential aration of cationic liposome-DNA complexes is a process injections of free liposomes and protamine-DNA might that is difficult to control, which might explain the large decrease the chance of interaction between the two variation for the in vivo lipofection by DOTAP liposomes.
components resulting in a decrease in gene expression. Cationic polymers behave differently from cationic lipoCurrently, it is not known how free liposomes interact somes in their interaction with DNA. They interact with with protamine-DNA complexes or with preformed LPD DNA in a more controllable manner which is less sensitive to the above-mentioned factors. 20 This might explain in vivo. Understanding this process might help to clarify the mechanism of in vivo lipofection and design better Injection of LPD Female CD-1 mice of 4-6 weeks of age were employed. formulations for intravenous applications.
While we were preparing this manuscript, several They were purchased from Charles River Laboratories (Wilmington, MA, USA) and were housed in accordance other liposome-DNA complexes were reported to give a high level of gene expression in the lung after i.v. adminwith institutional guidelines. Individual mice in groups of three were injected intravenously with 50 g of DNA istration. 30, 31 The activity varied with the cationic lipids employed, the size of liposomes and the helper lipids complexed with DOTAP alone, protamine alone or formulated in LPD in a total volume of 300 l 5% w/v gluused. When the same liposomes were used to prepare LPD, changes in each of those parameters were also cose. Twenty-four hours following i.v. injection, mice were killed and major organs were removed and assayed found to influence the in vivo activity of LPD. Yet, inclusion of protamine consistently increased the in vivo for gene expression. For intraportal injection, mice were anesthetized with inhalation of methoxyflurane activity of liposome-DNA complexes. More importantly, LPD was more stable upon storage and gave less toxicity (Mallinckrodt Veterinary, Mundelein, IL, USA) and intramuscular injection of ketamine hydrochloride (1 mg/20 g as compared with liposome-DNA complexes (Li and Huang, unpublished data). body weight). After the portal vein was exposed, 50 g of DNA formulated in LPD was administered using a In conclusion, a novel LPD composed of DOTAP, protamine and DNA has been developed in this study which tuberculin syringe with a 30-gauge .-inch needle. Gene expression in major organs was assayed 24 h following is highly efficient for in vivo gene transfer. The in vivo performance of LPD is charge ratio-dependent and also the injection. dose-dependent. Preliminary studies have shown that the LPD is quite stable and can be stored at 4°C for 4 weeks
Assay for luciferase activity The mice were bled from the retro-orbital sinuses under without losing its activity. Future studies are to search for more potent cationic lipids and/or to incorporate into anesthesia and were then killed by cervical dislocation. Heart, lung, spleen, liver and kidney were collected and LPD a component(s) which could further improve its in vivo transfection efficiency.
washed with cold saline twice. The organs were homogenized with lysis buffer (0.05% Triton X-100, 2 mm EDTA, 0.1 m Tris, pH 7.8) using a tissue tearor (Biospec
Materials and methods
Products, Bartlesville, OK, USA). After two cycles of freeze and thaw, the homogenates were centrifuged at 14 000 g for 10 min at 4°C and 20 l of the supernatant Chemicals was analyzed for luciferase activity using an Automated 1,2-Dioleoyl-3-trimethylammonium-propane (DOTAP) LB 953 luminometer equipped with an automated injecwas purchased from Avanti Lipid (Alabaster, AL, USA).
tor (Berthold, Bad Wildbad, Germany). Relative light Poly(l-lysine) (PLL) hydrobromide (MW 25 600), units (RLU) were converted to protein (pg) of luciferase protamine-free base and protamine phosphate were supusing purified enzyme (Calbiochem-Novabiochem, La plied by Sigma (St Louis, MO, USA). Protamine sulfateJolla, CA, USA) as a standard. Conversion was calculated USP was from Eli Lilly (Indianapolis, IN, USA). Luciferaccording to: luciferase (pg) = (8.3 × 10 −3 × RLU) − 5 (r 2 ase assay kit was obtained from Promega (Madison, WI, = 0.99). USA). All other chemicals were of reagent grade. DOTAP liposomes were prepared in filtered distilled water by X-gal staining sonication with a final concentration of 50 mg lipid/ml. Twenty four hours following the i.v. injection of pCMVLacZ formulated in LPD, the mice were killed and Plasmids lungs were perfused intravascularly with 2% paraformalPlasmids pCMVL and pCMVLacZ, which contain, dehyde and 0.1% glutaraldehyde and inflated with this respectively, the cDNA of firefly luciferase and bacterial mixture to near total lung capacity. After rinsing with ␤-galactosidase (␤-gal) driven by a human cytomegalocold PBS, the lungs were incubated in a staining solution virus immediate-early promoter, were amplified in (0.08% 5-bromo-4-chloro-3-indolyl-␤-d-galactoside, 5 mm DH5␣ strain of E coli, isolated by alkaline lysis and purof K 3 Fe(CN) 6, 2 mm MgCl 2 in PBS) at 37°C for 24 h. The ified by cesium chloride centrifugation. 32 lungs were then embedded in paraffin and thin sections were prepared. The sections were counterstained with hematoxylin eosin. Preparation of LPD and DOTAP-DNA complexes For preparation of LPD, DNA was diluted in distilled water and mixed with diluted protamine at a weight ratio
In vivo distribution of LPD Plasmid DNA was labeled with 125 I by using a published of 0.8 g of protamine per microgram of DNA. The mixture was allowed to stand at room temperature for 10 method. 33 DOTAP liposomes were labeled with 111
Indiethylenetriamine penta-acetic acid distearylamide commin. Different amounts of DOTAP liposomes were added to the solution and the mixture was incubated at room plex (DTPA-SA) as described. 34 Radiolabeled protamine-DNA complexes and LPD were prepared the same way temperature for another 10 min before use. LPD containing polylysine was similarly prepared. For preparation of as described above. Groups of three mice received i.v. injections of DOTAP liposomes, protamine-DNA com-DOTAP-DNA complexes, DOTAP liposomes were added to the diluted DNA in distilled water and the mixplexes or LPD. At different times following the injection, the mice were bled and killed by cervical dislocation. ture was incubated at room temperature for 10 min before use. The size of DOTAP-DNA complexes and LPD Major organs were collected and assayed for radioactivity. For dual-label studies, channel windows were set was determined by dynamic laser light scattering using a Coulter N4SD particle sizer (Hialeah, FL, USA).
to collect
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In and 125 I c.p.m. individually, and cross-talk
